Evidence map›Paper›PMID 34758609›Full record

ArticleHaematologica2022

Interferon α-induced SAMHD1 regulates human cultured megakaryocyte apoptosis and proplatelet formation.

Seema Bhatlekar, Shancy Jacob, Emilia Tugolukova, Bhanu K Manne, Yasuhiro Kosaka, Phillipe Loher, Ryan M O'Connell, Vicente Planelles, Matthew T Rondina, Isidore Rigoutsos and 1 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Seema BhatlekarProgram in Molecular Medicine and Department of Internal Medicine, University of Utah, Salt Lake City.
Shancy JacobProgram in Molecular Medicine and Department of Internal Medicine, University of Utah, Salt Lake City.
Emilia TugolukovaProgram in Molecular Medicine and Department of Internal Medicine, University of Utah, Salt Lake City.
Bhanu K ManneProgram in Molecular Medicine and Department of Internal Medicine, University of Utah, Salt Lake City, UT.
Yasuhiro KosakaProgram in Molecular Medicine and Department of Internal Medicine, University of Utah, Salt Lake City.
Phillipe LoherComputational Medicine Center, Thomas Jefferson University, Philadelphia.
Ryan M O'ConnellDivision of Microbiology and Immunology, Department of Pathology, and Huntsman Cancer Institute, University of Utah Health Sciences Center, University of Utah, Salt Lake City.
Vicente PlanellesDivision of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City.
Matthew T RondinaProgram in Molecular Medicine and Department of Internal Medicine, University of Utah, Salt Lake City, UT; Department of Pathology, University of Utah, Salt Lake City, UT and the George E. Wahlen VAMC Department of Medicine and George E. Wahlen VAMC GRECC, Salt Lake City.
Isidore RigoutsosDepartment of Pathology, University of Utah, Salt Lake City, UT and the George E. Wahlen VAMC Department of Medicine and George E. Wahlen VAMC GRECC, Salt Lake City.
Paul F BrayProgram in Molecular Medicine and Department of Internal Medicine, University of Utah, Salt Lake City, UT; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City. paul.bray@hsc.utah.edu.
University of Utah · USThomas Jefferson University · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Translational Control of Megakaryocyte and Platelet Gene Expression in DiseaseR35HL145237 · NHLBI · UNIVERSITY OF UTAH · PI WEYRICH, ANDREW S · 2019 to 2025
$4.7M
New Therapies to Restore Vascular Integrity During SepsisR01HL130541 · NHLBI · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J, WEYRICH, ANDREW S · 2016 to 2020
$3.7M
In vivo studies of megakaryocyte microRNAs regulating platelet number and integrin activationR01HL141424 · NHLBI · UNIVERSITY OF UTAH · PI BRAY, PAUL F. · 2018 to 2021
$2.5M
Tyrosine Kinase inhibition: The New Front in HIV Cure EffortsR01AI143567 · NIAID · UNIVERSITY OF UTAH · PI COIRAS, MAYTE, PLANELLES, VICENTE · 2019 to 2023
$2.3M
Translational Control of Megakaryocyte and Platelet Function in SepsisR01HL142804 · NHLBI · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2018 to 2021
$1.9M
MicroRNA function in human megakaryocytesR01HL116713 · NHLBI · UNIVERSITY OF UTAH · PI BRAY, PAUL F. · 2014 to 2017
$1.7M
Platelet Reprogramming During InflammationI01CX001696 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI Matthew Thomas Rondina · 2018 to 2026
–
CSRD VA I01 CX001696NCI NIH HHS P30 CA042014NHLBI NIH HHS R01 HL116713NHLBI NIH HHS R01 HL130541NHLBI NIH HHS R01 HL141424NHLBI NIH HHS R01 HL142804NHLBI NIH HHS R35 HL145237NIAID NIH HHS R01 AI143567
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Blood PlateletsInterferon-alphaMegakaryocytesSAM Domain and HD Domain-Containing Protein 1ApoptosisCells, CulturedHumansInterferon-alphaSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, human

Identifiers

PMID34758609
PMCPMC8804568
OpenAlexW3211803098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.